Apellis Pharmaceuticals, Inc. (APLS) Earnings History
Annual and quarterly earnings data from 2013 to 2025
Loading earnings history...
APLS EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
APLS Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | 89.8% | 5.5% | 2.2% |
| 2024 | 84.9% | -21.1% | -25.3% |
| 2023 | 85.2% | -130.4% | -133.3% |
| 2022 | 92.5% | -788.4% | -864.7% |
| 2021 | 92.2% | -805.7% | -1121.3% |
Download Data
Export APLS earnings history in CSV or JSON format
Free sign-in required to download data
Apellis Pharmaceuticals, Inc. (APLS) Earnings Overview
As of May 8, 2026, Apellis Pharmaceuticals, Inc. (APLS) reported trailing twelve-month net income of $133M, reflecting +111.3% year-over-year growth. The company earned $0.18 per diluted share over the past four quarters, with a net profit margin of 2.2%.
Looking at the long-term picture, APLS's historical earnings data spans multiple years. The company achieved its highest annual net income of $22M in fiscal 2025, representing a new all-time high.
Apellis Pharmaceuticals, Inc. maintains positive profitability with a gross margin of 89.8%, operating margin of 5.5%, and net margin of 2.2%. The company continues to generate positive earnings from operations. View revenue history →
Compared to peers including RARE (-$609M net income, -85.4% margin), BEAM (-$65M net income, -57.2% margin), AKRO (-$293M net income), APLS has outperformed on profitability metrics. Compare APLS vs RARE →
APLS Earnings vs Peers
Earnings metrics vs comparable public companies
APLS Historical Earnings Data (2013–2025)
13 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $22M | +111.3% | $55M | $0.18 | 2.2% | 5.5% |
| 2024 | -$198M | +62.6% | -$165M | $-1.60 | -25.3% | -21.1% |
| 2023 | -$529M | +18.9% | -$517M | $-4.45 | -133.3% | -130.4% |
| 2022 | -$652M | +12.6% | -$595M | $-6.15 | -864.7% | -788.4% |
| 2021 | -$746M | -116.4% | -$536M | $-8.84 | -1121.3% | -805.7% |
| 2020 | -$345M | -13.2% | -$214M | $-4.59 | -137.6% | -85.3% |
| 2019 | -$305M | -139.0% | -$288M | $-4.98 | - | - |
| 2018 | -$128M | -150.0% | -$128M | $-2.34 | - | - |
| 2017 | -$51M | -88.0% | -$51M | $-1.49 | - | - |
| 2016 | -$27M | +41.7% | -$27M | $-1.50 | - | - |
See APLS's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs APLS Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare APLS vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonAPLS — Frequently Asked Questions
Quick answers to the most common questions about buying APLS stock.
Is APLS growing earnings?
APLS EPS is $0.18, with earnings growth accelerating to +111.3%. This exceeds the 5-year CAGR of N/A. TTM net income reached $133M.
What are APLS's profit margins?
Apellis Pharmaceuticals, Inc. net margin is +2.2%, with operating margin at +5.5%. Below-average margins reflect competitive or cost pressures.
How consistent are APLS's earnings?
APLS earnings data spans 2013-2025. The accelerating earnings trend is +111.3% YoY. Historical data enables comparison across business cycles.